Sage Journals: Discover world-class research

Abstract

Get full access to this article

View all access options for this article.

References

Bailey

. New therapies for diabesity. Curr Diab Rep. 2009;9:360–367.

Farag

Gaballa

. Diabesity: an overview of a rising epidemic. Nephrol Dial Transplant. 2011;26:28–35.

Kaufman

. Diabesity in children. In: Gellman

Turner

, eds. Encyclopedia of Behavioral Medicine. New York: Springer; 2013:575–577.

Kurland

Accili

Burant

. Application of combined omics platforms to accelerate biomedical discovery in diabesity. Ann N Y Acad Sci. 2013;1287:1–16.

Will

Hornigold

Baker

. Gut check on diabesity: leveraging gut mechanisms for the treatment of type 2 diabetes and obesity. Curr Opin Pharmacol. 2017;37:10–15.

Pappachan

Viswanath

. Medical management of diabesity; do we have realistic targets? Curr Diab Rep. 2017;17:4.

Kahn

Hull

Utzschneider

. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444:840–846.

Montague

O’Rahilly

. The perils of portliness. Causes and consequences of visceral adiposity. Diabetes. 2000;49:883–888.

Cardillo

. Drug treatments to restore vascular function and diabesity. Ann Pharm Fr. 2013;71:27–33.

10.

García-Fernández

Rico-Cabanas

Rosgaard

Estruch

Bach-Faig

. Mediterranean diet and cardiodiabesity: a review. Nutrients. 2014;6:3474–3500.

11.

Gellman

Turner

, eds. Encyclopedia of Behavioral Medicine. New York: Springer; 2013.

12.

Turner

. Transitions, introductions, and a notable announcement from the US FDA in December 2916. Therapeutic Innovation & Regulatory Science. 2017;51:140–141.

13.

Meigs

. Epidemiology of cardiovascular complications in type 2 diabetes. Acta Diabetol. 2003;40: S358–S361.

14.

Geiger

Mehta

Turner

. Clinical development and statistical approaches to assessing cardiovascular risk of new type 2 diabetes therapies. Therapeutic Innovation & Regulatory Science. 2015;49:50–64.

15.

Herbst

Bolton

Shariff

Green

. Cardiovascular outcome trial update in diabetes: new evidence, remaining questions. Curr Diab Rep. 2017;17:67.

16.

Zinman

Wanner

Lachin

; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.

17.

FDA. News Release, 12 2, 2016. FDA approves Jardiance to reduce cardiovascular death in adults with type 2 diabetes. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm531517.htm. Published 2016. Accessed November 14, 2017.

18.

FDA. Approval letter. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022341s000approv.pdf. Published 2010. Accessed November 15, 2017.

19.

Marso

Daniels

Brown-Frandsen

; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–322.

20.

PR Newswire. Janssen submits supplemental New Drug Application. https://www.prnewswire.com/news-releases/janssen-submits-supplemental-new-drug-application-snda-to-us-fda-seeking-new-indication-for-invokana-canagliflozin-to-reduce-the-risk-of-major-adverse-cardiovascular-events-mace-based-on-landmark-canvas-program-300528971.html. Published October 2, 2017. Accessed November 17, 2017.

21.

Neal

Perkovic

Mahaffey

. CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–657.

22.

ClinicalTrials.gov. Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events (DECLARE-TIMI 58). https://www.clinicaltrials.gov/ct2/show/NCT01730534?term=TIMI+declare&rank=1. Published September 18, 2017. Accessed November 17, 2017.

23.

Novo Nordisk. Semaglutide receives positive 16-0 vote in favour of approval from FDA Advisory Committee. Available at: https://www.novonordisk.com/media/news-details.2142854.html. Published October 18, 2017. Accessed November 15, 2017.

24.

Marso

Bain

Consoli

. SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–1844.

25.

Holman

Bethel

Mentz

; EXSCEL Study Group. Effects of once-weekly Exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377:1228–1239.

26.

Bays

Pi-Sunyer

Hemmingsson

. Liraglutide 3.0 mg for weight management: weight-loss dependent and independent effects. Curr Med Res Opin. 2017;33:225–229.

27.

Santilli

Simeone

Guagnano

. Effects of liraglutide on weight loss, fat distribution, and β-cell function in obese subjects with prediabetes or early type 2 diabetes. Diabetes Care. 2017;40:1556–1564.

28.

Caveney

Somaratne

Turner

Gourgiotis

. Pharmaceutical interventions for obesity: a public health perspective. Diabetes Obes Metab. 2011;13:490–497.

29.

Hocking

Dear

Cowley

. Current and emerging pharmacotherapies for obesity in Australia. Obes Res Clin Pract. 2017;11:501–521.

30.

Wanner

Inzucchi

Lachin

; EMPA-REG OUTCOME investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323–334.

31.

Fitchett

Zinman

Wanner

; EMPA-REG OUTCOME® trial investigators. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J. 2016;37:1526–1534.

32.

Zinman

Inzucchi

Lachin

; EMPA-REG OUTCOME Investigators (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients). Empagliflozin and cerebrovascular events in patients with type 2 diabetes mellitus at high cardiovascular risk. Stroke. 2017;48:1218–1225.

33.

Fitchett

Zinman

Wanner

34.

Wanner

Lachin

Inzucchi

: EMPA-REG OUTCOME® investigators. Empagliflozin and clinical outcomes in patients with type 2 diabetes, established cardiovascular disease and chronic kidney disease [published online September 13, 2017]. Circulation. doi:10.1161/CIRCULATIONAHA.117.028268.

35.

Butler

Hamo

Filippatos

; EMPEROR Trials Program. The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. Eur J Heart Fail. 2017;19:1390–1400.

36.

Mann

JFE

Ørsted

Brown-Frandsen

; LEADER Steering Committee and Investigators. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017;377:839–848.

37.

Schernthaner

Lehmann

Prázný

. Translating recent results from the cardiovascular outcomes trials into clinical practice: recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG). Cardiovasc Diabetol. 2017;16:137.

Cardiodiabesity and Related Updates

Abstract

Get full access to this article

References